Genghis Lloyd-Harris

Genghis is a physician, scientist and investor with over 30 years of transatlantic industry experience in finance and venture capital, across biopharmaceuticals, clinical co-development, life science tools and medical devices. 

Genghis is a senior advisor at leading life sciences investment firm Abingworth, where he identifies and invests in new businesses and supports portfolio companies. He focuses on exits of venture investments via mergers and acquisitions and IPOs. Genghis’ current and past board positions include Avillion, GenSight Biologics, Healthcare Brands International, Nouscom, Novexel, Solexa, Synosia, Syntaxin and Wilson Therapeutics. 

Genghis joined Abingworth in 2004 from Credit Suisse First Boston where he was managing director in the European Equity Research Group based in London responsible for coverage of the European biotechnology industry.  

Genghis was a paediatrician in Melbourne, Australia and holds a Medical Degree from the University of Liverpool, a PhD in Clinical Pharmacology from the University of Melbourne and an MBA from Harvard Business School.